The Mounjaro NHS Roll Out Explained

Which patients does the current NHS Mounjaro roll out actually cover?

NICE approved tirzepatide for NHS use in England in December 2024 (Technology Appraisal TA1026), but access is being phased rather than opened to everyone at once. The first cohort became eligible in June 2025: adults with a BMI of 40 or above who have four or more of five specific weight-related conditions, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. That's a deliberately narrow starting point, covering the people with the highest clinical need.

The second cohort opened on 23 June 2026: BMI 35–39.9 plus four or more of those same five conditions. So if you sit in that range and carry multiple comorbidities, you may now be in scope for the first time. You can read the full eligibility criteria in NICE's recommendation for tirzepatide (TA1026).

One thing the criteria don't spell out: even if you qualify on paper, your GP practice has to have opted into the new contract arrangements. Participation is voluntary, so access still varies by area. Worth a direct conversation with your surgery rather than assuming it's available.

What's coming next in the NHS Mounjaro roll out?

The planned third cohort would lower the condition requirement to three of the five, while keeping the BMI at 40 or above, expected around March 2027. Further phases beyond that have been outlined but not yet formally dated.

For context on how the NHS is structuring the wider obesity medicines programme, NHS England's guidance on weight-management injections covers the wraparound diet and activity support that must accompany any prescription. That support isn't optional, it's built into the terms of the NHS programme, and patients who don't engage with it may not continue to receive the medicine.

Scotland, Wales and Northern Ireland operate their own processes with different thresholds, so if you're outside England the NHS picture will differ. The NHS Mounjaro roll out pages are England-specific; check with your local health board for devolved-nation criteria.

If the timelines feel frustrating, that's understandable. These phased cohorts are partly a supply and workforce decision, not just a clinical one. The private route exists precisely for people who meet the licensed eligibility criteria but fall outside the NHS cohort for now, more on that below.

Can I get Mounjaro on the NHS through my GP right now?

Possibly, but it depends on your practice and your local integrated care board. From 1 April 2026, GP practices in England can prescribe tirzepatide under the new QOF contract arrangements, which is a significant shift from the previous specialist-service-only model. Our guide to getting Mounjaro through your GP sets out what to ask and what to bring to the appointment.

Even practices that have signed up may have waiting lists, formulary constraints, or a preference for referring patients to a structured weight management service first. There's no single national booking system you can check online; the honest answer is that it requires a direct conversation with your surgery. If you've already had that conversation and been told the wait is long, you're not alone, our page on Mounjaro on the NHS covers the landscape in more detail.

One practical note: if you'd like to explore whether the private route is right for you while you wait, a consultation with a registered prescriber takes less than a day to complete. What actually arrives (a discrete plain box, DPD tracking sent to your phone, the Mounjaro KwikPen inside) is the same licensed medicine from the same UK supply chain, just without the referral queue. Information on how to buy Mounjaro through a regulated online pharmacy explains what to look for.

Is private Mounjaro a realistic option if I don't qualify for the NHS roll out yet?

For many people, yes. The licensed private eligibility criteria are broader than the current NHS cohort: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as prediabetes, hypertension or high cholesterol. A prescriber makes the final call after reviewing your full health picture, BMI alone is not an automatic green light.

Cost is the main consideration. Private prices vary by provider and dose; our breakdown of Mounjaro pricing in the UK covers what the market actually looks like and what a legitimate price should include (consultation, prescription, clinical review, delivery, not just the pen). If you're weighing up whether buying Mounjaro on the NHS is still the right path for you before committing to private treatment, that page walks through how the two routes compare. For a sense of all available treatment options alongside tirzepatide, the treatment overview is the right place to start.

A word on safety when buying privately: Mounjaro is a prescription-only medicine, which means any seller offering it without a proper clinical assessment is operating outside the law. The MHRA has warned repeatedly about counterfeit weight-loss pens circulating online; if you've heard reports of Mounjaro being out of stock and are tempted by unverified sellers as a result, confirming any pharmacy on the GPhC register before handing over payment is the safest step you can take. At nume, our GPhC registration number is 9012878, verifiable directly on the register. Every consultation is read the same day by a real prescriber, not processed by an algorithm.